Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study
Top Cited Papers
Open Access
- 1 October 2016
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 13 (4) , 824-832
Abstract
No abstract availableKeywords
Funding Information
- SNUH Research Fund (25-2014-0040, 03-2015-0430)
- Korea National Institute of Health (HI14C25020000, HI12C1544)
This publication has 37 references indexed in Scilit:
- Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigensJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognitionJournal of Neurology, Neurosurgery & Psychiatry, 2012
- The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis ProjectClinical Infectious Diseases, 2012
- Encephalitis and antibodies to synaptic and neuronal cell surface proteinsNeurology, 2011
- Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II studyHaematologica, 2010
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension studyAnnals of the Rheumatic Diseases, 2009
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- INTERLEUKIN-6: From Basic Science to Medicine—40 Years in ImmunologyAnnual Review of Immunology, 2005
- Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2005